Semaglutide improves blood vessel function in Japanese T2DM patients independently of weight, glucose, or cholesterol changes
In 24 Japanese T2DM patients, once-weekly semaglutide significantly improved vascular endothelial function (RHI 1.62→2.04, p<0.01) independently of concurrent improvements in weight, HbA1c, and LDL cholesterol.
Quick Facts
What This Study Found
RHI: 1.62±0.19 → 2.04±0.60 (p<0.01). BW, HbA1c, LDL-cho also improved (all p<0.01). hsCRP trended down (NS). No correlation between metabolic changes and RHI improvement. 24 patients, mean age 55, 83% male.
Key Numbers
How They Did This
Retrospective observational study at Jinnouchi Hospital (Japan). 24 T2DM patients initiated on once-weekly SC semaglutide since 2021. RHI by EndoPAT. Clinical parameters before and after treatment.
Why This Research Matters
Endothelial dysfunction is the earliest step in atherosclerosis. Demonstrating that semaglutide directly improves endothelial function—independent of metabolic improvements—reveals a direct vascular protective mechanism.
The Bigger Picture
This adds direct endothelial protection to semaglutide's cardiovascular benefit portfolio. The lack of correlation with metabolic changes suggests a novel, independent vascular mechanism.
What This Study Doesn't Tell Us
Small sample (24). Retrospective. No control group. Japanese population. RHI has measurement variability. Follow-up duration not specified.
Questions This Raises
- ?What direct mechanism improves endothelial function independently of metabolic effects?
- ?Would this translate to reduced atherosclerosis progression on imaging?
- ?Do other GLP-1 drugs show the same direct vascular effect?
Trust & Context
- Key Stat:
- Direct vascular protection Semaglutide improved endothelial function independently of metabolic improvements—suggesting a direct GLP-1-mediated vascular protective effect beyond glucose and weight control
- Evidence Grade:
- Small retrospective observational study. Novel finding but needs larger confirmation.
- Study Age:
- Published in 2025.
- Original Title:
- Once-Weekly Semaglutide Is Associated With Improvement in Vascular Endothelial Function in Patients With Type 2 Diabetes Mellitus: A Retrospective Observational Study.
- Published In:
- Cureus, 17(12), e99998 (2025)
- Authors:
- Sugiyama, Seigo, Yoshida, Akira, Kurinami, Noboru, Hieshima, Kunio, Jinnouchi, Katsunori, Suzuki, Tomoko, Miyamoto, Fumio, Kajiwara, Keizo, Jinnouchi, Hideaki
- Database ID:
- RPEP-13702
Evidence Hierarchy
Frequently Asked Questions
Does semaglutide protect blood vessels?
Yes. This study measured blood vessel health directly using a reactive hyperemia test and found semaglutide significantly improved vascular function. Importantly, this improvement was independent of weight loss, blood sugar, or cholesterol changes—suggesting a direct protective effect on blood vessel walls.
What is endothelial function and why does it matter?
The endothelium is the inner lining of blood vessels. When it functions well, blood flows smoothly and vessel walls resist plaque buildup. When damaged (endothelial dysfunction), atherosclerosis begins. Semaglutide's ability to improve endothelial function may explain part of its cardiovascular protective effects.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-13702APA
Sugiyama, Seigo; Yoshida, Akira; Kurinami, Noboru; Hieshima, Kunio; Jinnouchi, Katsunori; Suzuki, Tomoko; Miyamoto, Fumio; Kajiwara, Keizo; Jinnouchi, Hideaki. (2025). Once-Weekly Semaglutide Is Associated With Improvement in Vascular Endothelial Function in Patients With Type 2 Diabetes Mellitus: A Retrospective Observational Study.. Cureus, 17(12), e99998. https://doi.org/10.7759/cureus.99998
MLA
Sugiyama, Seigo, et al. "Once-Weekly Semaglutide Is Associated With Improvement in Vascular Endothelial Function in Patients With Type 2 Diabetes Mellitus: A Retrospective Observational Study.." Cureus, 2025. https://doi.org/10.7759/cureus.99998
RethinkPeptides
RethinkPeptides Research Database. "Once-Weekly Semaglutide Is Associated With Improvement in Va..." RPEP-13702. Retrieved from https://rethinkpeptides.com/research/sugiyama-2025-onceweekly-semaglutide-is-associated
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.